bad medical devices blog

Search

Topics

Uncategorized

Links
- FDA

Case Review Form

* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of injured person
(mm-dd-yyyy):

Name of medical device:

Please describe any problems or injuries caused by the device:

Other Info:

No Yes, I agree to the Parker & Waichman, LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker & Waichman, LLP monthly newsletter, InjuryAlert.

Archives

Latest Medical Device News

6 French Engage Introducer Devices by St. Jude Medical: Recall - Potential for Separation of Shaft From Hub - Potentially life threatening episode of bleeding could occur during surgical procedures.
Combat Application Tourniquets (C-A-T): Suspected Counterfeit Product - Suspected counterfeit product is weaker, and breaks or bends before necessary force can be applied to stop blood flow. Excessive blood loss can endanger the victim’s life and ultimately lead to death.
Cook brand Ciaglia Blue Rhino/Ciaglia Blue Dolphin Percutaneous Tracheostomy Introducer Sets and Trays - UPDATE 08/04/2010. Recall classified as Class I - balloon inflation assembly may not hold air. Originally posted 07/22/2010
Fingerstick Devices to Obtain Blood Specimens: Initial Communication - Risk of Transmitting Bloodborne Pathogens - Increase in reports of bloodborne infection transmission resulting from the shared use of fingerstick and point-of-care blood testing devices.
Huber Needles: Recall - Risk of Coring - Risk of infection, damage or death of tissue, swelling, or other serious adverse health consequences occurring as a result of the core travelling through blood vessels into the patient’s lungs.
INOMAX DS Drug-Delivery System: Class I Recall - Risk of Interruption of Drug Flow - Potential for failure of a pressure switch, which may have an impact on the administration of INOMAX for inhalation to patients.
Inferior Vena Cava (IVC) Filters: Initial Communication: Risk of Adverse Events with Long Term Use - Known long term risks associated with IVC filters include lower limb deep vein thrombosis, filter fracture, filter migration, filter embolization and IVC perforation.
Lamictal (lamotrigine): Label Change - Risk of Aseptic Meningitis - Warnings and Precautions section of Prescribing Information and patient Medication Guide revised to include information about the risk of aseptic meningitis.
MasXtreme Capsules (Natural Wellness) - product contains undeclared drug ingredient - UPDATED 08/25/2010. Product marketed as dietary supplement contains undeclared Aminotadalafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.
Midodrine hydrochloride: FDA Proposes Withdrawal of Low Blood Pressure Drug - Companies failed to provide evidence of clinical benefit of midodrine hydrochloride because required post-approval studies that verify the clinical benefit of the drug have not been done.
Mr. Magic Male Enhancer: Undeclared Drug Ingredient - Product marketed as dietary supplement contains undeclared hydroxythiohomosildenafil and sulfoaildenafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.
Novacare LLC Products: Recall - Undeclared Drug Ingredient - Products marketed as dietary supplement sexual enhancers for men contain undeclared sulfoaildenafil, which may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels.
Octagam (Immune Globulin Intravenous (human)) 5% Liquid Preparation: Market Withdrawal - Risk of Thromboembolic Events - Customers asked to immediately quarantine the use of affected lots due to the potential for serious thromboembolic events.
Prolatis’: Undeclared Drug Ingredient - Product marketed as dietary supplement contains undeclared sulfoaildenafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.
Qualaquin (quinine sulfate): New Risk Evaluation and Mitigation Strategy - Risk of serious hematological reactions - UPDATE 08/04/2010. Dear Healthcare Professional Letter issued. New Risk Management Plan. Reports of serious side effects in patients using Qualaquin "off-label" for night time leg cramps. Originally posted 07/08/2010
Revivexxx Extra Strength: Recall - Undeclared Drug Ingredient - Product marketed as a dietary supplement sexual enhancer for men contains undeclared tadalafil, which may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels.
Solo Slim, Solo Slim Extra Strength: Recall - Undeclared Drug Ingredient - Product contains undeclared didesmethyl sibutramine, which may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.
Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk - FDA evaluating clinical trial data that suggest patients taking drug may be at an increased risk for cardiovascular events compared to those taking carbidopa/levodopa
TimeOut Capsules: Undeclared Drug Ingredient - Product marketed as dietary supplement contains undeclared hydroxythiohomosildenafil, a chemical similar to sildenafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.
Tygacil (tigecycline): Label Change - Increased Mortality Risk - Healthcare professionals should consider alternatives to Tygacil in patients with severe infections.

Rhode Island jury awards $1.5 million for Kugel Mesh patch injuries

September 1st, 2010 joshua

A Rhode Island jury has awarded $1.5 million to two people who suffered injuries as a result of the defective Composix® Kugel® Mesh hernia repair patch.

The jury agreed with the attorneys for Christopher and Laure Thorpe that a defective design of the hernia patch manufactured by Davol Inc. and C.R. Bard Inc. The plaintiffs were awarded $1.3 million by the jury for personal injury damages and another $200,000 for loss of consortium.

This is the second of two cases against Davol and C.R. Bard for their defective design of the patch and the fact that each hid dangers of the medical device from regulators and the public.

Christopher Thorpe suffered severe internal injuries due to a broken plastic ring on the mesh patch. Those injuries included an abdominal wall abscess and fistula.

Thorpe had to endure multiple surgeries to repair the damages, but still suffers from the original injuries.

In late 2005 and early 2006, the device makers were forced to recall certain Lots of these mesh hernia patches because a plastic piece that allows the patch to open once inside the body would break off from sustained pressure. This runaway piece caused severe injuries to thousands of people who have similar personal injury lawsuits against its makers.

These bellwether trials in Rhode Island - two more are scheduled - will ultimately decide the result of many of those lawsuits. The current trend represents good news for those injured by this device.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.